| Item type |
文献 / Documents(1) |
| 公開日 |
2023-12-20 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/1759-7714.14314 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1111/1759-7714.14314 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer |
|
言語 |
en |
| 著者 |
コンドウ, ヨシヒロ
國重, 道大
カドタ, ナオキ
オカノ, ヨシオ
マチダ, ヒサノリ
ハタケヤマ, ノブオ
ナルセ, ケイシ
篠原, 勉
タケウチ, エイジ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Profound and durable responses to a single dose of pembrolizumab in lung cancer are rare. We encountered a non-small cell lung cancer patient showing a deep and durable response with a single dose of pembrolizumab. A 79-year-old man reported bloody sputum for several weeks and visited a general physician. A chest x-ray revealed a tumor shadow in the right middle lung field at that time, and the patient was referred to our hospital. He was diagnosed with adenocarcinoma of the lung by transbronchial biopsy. The expression of programmed death ligand 1 in tumor cells was 100% by immunostaining. Based on the above, immunotherapy with pembrolizumab was performed as first-line therapy. Cancer cells had significantly shrunk at the end of the first cycle. The patient had grade-3 immune-related hepatitis at the end of the first cycle. Pembrolizumab treatment was stopped and prednisolone (80 mg/body) was initiated. Subsequently, liver function normalized, and prednisolone was tapered and discontinued. Since then, no tumor recurrence has been detected for 1.5 years without treatment. There have been few reports of profound and durable responses to a single dose of pembrolizumab in lung cancer. The results indicate that a single dose of pembrolizumab alone may be sufficient to cause durable response and serious immune-related adverse events in some cases. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
durable response |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
immune-related hepatitis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
non-small cell lung cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pembrolizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
single dose |
| 書誌情報 |
en : Thoracic Cancer
巻 13,
号 4,
p. 648-652,
発行日 2022-01-12
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597714 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597706 |
| 出版者 |
|
|
出版者 |
China Lung Oncology Group |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
John Wiley & Sons Australia |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| EID |
|
|
識別子 |
397304 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
tc_13_4_648.pdf (1.27 MB)
.png)
